Latest News

FT reports that activist hedge fund Parvus has acquired a stake in Novo Nordisk.

The Financial Times reported that the activist hedge fund Parvus Asset Management has built a stake in Novo Nordick after the company lost the first mover advantage on the lucrative market for weight loss drugs, according to people familiar with the details.

Reports claim that the London-based fund has been targeting the budget airline Ryanair as well as the Italian bank UniCredit to influence the nomination of Novo Nordisk’s new CEO.

In an email, Novo said that it "has nothing to add." Parvus didn't immediately respond to an inquiry for comment.

In May, Novo announced that its CEO Lars Fruergaard Jorgensen will step down. Shares had plummeted from their record high in June of last year, as the competition, notably from U.S. competitor Eli Lilly, made inroads on Novo's share. Meanwhile, its pipeline for new drugs failed to impress investors.

Last month, after cutting its forecasts for 2025, Jorgensen stated that Novo expects Wegovy sales to begin recovering in the United States once the ban on compound copies is implemented this month.

(source: Reuters)